×
About 96,596 results

ALLMedicine™ Small Cell Lung Cancer Center

Research & Reviews  44,675 results

Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating ...
https://doi.org/10.1016/j.jtho.2021.04.018
Journal of Thoracic Oncology : Official Publication of Th... Fan C, Zhao Q et. al.

May 14th, 2021 - We aimed to examine the efficacy and safety of intrathecal pemetrexed (IP) for treating EGFR-mutant leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC). EGFR-mutant NSCLC patients with LM who had failed tyrosine-kina...

Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constra...
https://doi.org/10.1016/j.ijrobp.2020.09.015
International Journal of Radiation Oncology, Biology, Phy... Tsao MN, Louie AV

May 14th, 2021 - Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constrained by Constraints!|2021|Tsao MN,Louie AV,|

The circular RNA circ_GRHPR promotes NSCLC cell proliferation and invasion via interact...
https://doi.org/10.1111/1440-1681.13523
Clinical and Experimental Pharmacology & Physiology; Hou Y, Lin J et. al.

May 14th, 2021 - As the most common malignancy, lung cancer is characterised by high rates of occurrence and mortality. Although circular RNAs (circRNAs) are known to act as important regulators in cancer, their role in lung cancer remains poorly understood. In th...

Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patien...
https://doi.org/10.1016/j.jtcvs.2021.02.099
The Journal of Thoracic and Cardiovascular Surgery; Tong BC, Gu L et. al.

May 14th, 2021 - Pembrolizumab is a programmed death receptor-1 masking antibody approved for metastatic non-small cell lung cancer. This Phase 2 study (NCT02818920) of neoadjuvant pembrolizumab in non-small cell lung cancer had a primary end point of safety and s...

Optical tweezers study of membrane fluidity in small cell lung cancer cells.
https://doi.org/10.1364/OE.420288
Optics Express; Li X, Chen Z et. al.

May 14th, 2021 - The fluidity of the cell membrane is closely related to cancer metastasis/invasion. To test the relationship of membrane fluidity and invasiveness, we first demonstrated that transfection of small RNA miR-92b-3p can significantly increase invasive...

see more →

Guidelines  283 results

Prophylactic cranial irradiation for extensive‐stage small cell lung cancer
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014559/full
Cochrane Database of Systematic Reviews; Nishie K

Mar 17th, 2021 - To assess the effectiveness and safety of PCI plus standard treatment compared to standard treatment alone in people with ED‐SCLC who have responded to first‐line chemotherapy.

Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis
https://pubmed.ncbi.nlm.nih.gov/33759443/
Minerva Endocrinology; Fan H, et ak

Mar 15th, 2021 - To compare survival outcome among the patients with concurrent small cell lung cancer (SCLC) and diabetes mellitus (DM) using metformin or without metformin.

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844954/
Systematic Reviews; Winther-Larsen A

Jan 27th, 2021 - Inflammation scores based on general inflammation markers as leucocyte count or C-reactive protein have been evaluated as prognostic markers of inferior survival in several cancers. In small cell lung cancer (SCLC), however, inflammation scores ar...

Small Cell Lung Cancer - StatPearls
https://www.statpearls.com/articlelibrary/viewarticle/24494/
StatPearls [Internet];

Dec 31st, 2020 - Lung cancer is the second most diagnosed cancer in the United States. It is the leading cause of cancer death in both men and women, accounting for approximately a quarter of all cancer deaths. Lung cancer is histologically divided into 2 main typ...

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
https://pubmed.ncbi.nlm.nih.gov/32746691/
Journal of Oncology Pharmacy Practice; Rosentreter J

Aug 2nd, 2020 - Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from...

see more →

Drugs  331 results see all →

Clinicaltrials.gov  48,755 results

Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating ...
https://doi.org/10.1016/j.jtho.2021.04.018
Journal of Thoracic Oncology : Official Publication of Th... Fan C, Zhao Q et. al.

May 14th, 2021 - We aimed to examine the efficacy and safety of intrathecal pemetrexed (IP) for treating EGFR-mutant leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC). EGFR-mutant NSCLC patients with LM who had failed tyrosine-kina...

Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constra...
https://doi.org/10.1016/j.ijrobp.2020.09.015
International Journal of Radiation Oncology, Biology, Phy... Tsao MN, Louie AV

May 14th, 2021 - Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constrained by Constraints!|2021|Tsao MN,Louie AV,|

The circular RNA circ_GRHPR promotes NSCLC cell proliferation and invasion via interact...
https://doi.org/10.1111/1440-1681.13523
Clinical and Experimental Pharmacology & Physiology; Hou Y, Lin J et. al.

May 14th, 2021 - As the most common malignancy, lung cancer is characterised by high rates of occurrence and mortality. Although circular RNAs (circRNAs) are known to act as important regulators in cancer, their role in lung cancer remains poorly understood. In th...

Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patien...
https://doi.org/10.1016/j.jtcvs.2021.02.099
The Journal of Thoracic and Cardiovascular Surgery; Tong BC, Gu L et. al.

May 14th, 2021 - Pembrolizumab is a programmed death receptor-1 masking antibody approved for metastatic non-small cell lung cancer. This Phase 2 study (NCT02818920) of neoadjuvant pembrolizumab in non-small cell lung cancer had a primary end point of safety and s...

Optical tweezers study of membrane fluidity in small cell lung cancer cells.
https://doi.org/10.1364/OE.420288
Optics Express; Li X, Chen Z et. al.

May 14th, 2021 - The fluidity of the cell membrane is closely related to cancer metastasis/invasion. To test the relationship of membrane fluidity and invasiveness, we first demonstrated that transfection of small RNA miR-92b-3p can significantly increase invasive...

see more →

News  2,541 results

Fast Five Quiz: Squamous Cell Non-Small Cell Lung Cancer
https://reference.medscape.com/viewarticle/928233

May 4th, 2021 - Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Non–small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is divided histologically into adenocarcinoma, squamous cell carcinoma, and large cel...

Superior Survival With Sintilimab in Squamous NSCLC
https://www.medscape.com/viewarticle/950480

May 3rd, 2021 - Second-line treatment with sintilimab improved survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer (sqNSCLC) in a phase 3 trial. Sintilimab improved both overall survival (OS) and progre...

Small Cell Lung Cancer Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/950185

Apr 28th, 2021 - Updated guidelines on diagnosis, treatment, and follow-up of small cell lung cancer (SCLC) were published on April 9, 2021 by the European Society for Medical Oncology (ESMO) in the Annals of Oncology.[1] Diagnosis SCLC should be diagnosed accordi...

Tislelizumab Bests Docetaxel in NSCLC
https://www.medscape.com/viewarticle/949726

Apr 21st, 2021 - As second- or third-line therapy in patients with locally advanced non–small cell lung cancer (NSCLC), tislelizumab was well tolerated and prolonged overall survival (OS), compared with docetaxel in the phase 3 RATIONALE 303 study. The results wer...

Drug Duo Targeting ATR Enzyme Shrinks Small Cell Lung Cancer Tumors
https://www.medscape.com/viewarticle/949638

Apr 20th, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...

see more →

Patient Education  11 results see all →